Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sagar Lonial, a myeloma specialist from the Emory University, to discuss the recent FDA approval of iberdomide, a novel cereblon modulator (CELMoDs), in combination with daratumumab and dexamethasone for the treatment of relapsed and refractory multiple myeloma.

Join us as we dive into:

The significance of the EXCALIBER-RRMM study that led to the approval of iberdomide
What makes cereblon modulators different from existing immunomodulatory agents (IMiDs) and their potential benefits
The study design, findings, and the implications of minimal residual disease (MRD) as a primary endpoint for approval
Who the ideal candidates for iberdomide are and how it fits into the current treatment landscape
The side effect profile of iberdomide compared to traditional therapies and management strategies
Insights on monitoring disease status and the future of cereblon modulators in combination with other therapies

This episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in multiple myeloma treatment.

Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

X/Twitter: https://x.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#CELMoDs, #MultipleMyeloma, #EXCALIBERstudy, #MRD, #OncologyBrothers

EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial

Oncology Brothers: Practice-Changing Cancer Discussions

EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial